Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rodgers, Barbara A
STOP360AG, NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study	Recruiting	4	730	Canada, US	Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG	Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation	Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation	11/26	11/26
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003	Completed	1	51	US	ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.	Anagram Therapeutics, Inc.	Exocrine Pancreatic Insufficiency	07/24	07/24
CHEC-SC, NCT03350828: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes	Active, not recruiting	N/A	5000	US		Nicole Hamblett, Cystic Fibrosis Foundation	Cystic Fibrosis	12/26	12/26